We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Seeking Clues to Prestige Consumer Healthcare (PBH) Q1 Earnings? A Peek Into Wall Street Projections for Key Metrics
Read MoreHide Full Article
Wall Street analysts forecast that Prestige Consumer Healthcare (PBH - Free Report) will report quarterly earnings of $0.87 per share in its upcoming release, pointing to a year-over-year decline of 17.9%. It is anticipated that revenues will amount to $260.07 million, exhibiting a decline of 6.9% compared to the year-ago quarter.
Over the last 30 days, there has been no revision in the consensus EPS estimate for the quarter. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Before a company reveals its earnings, it is vital to take into account any changes in earnings projections. These revisions play a pivotal role in predicting the possible reactions of investors toward the stock. Multiple empirical studies have consistently shown a strong association between trends in earnings estimates and the short-term price movements of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
With that in mind, let's delve into the average projections of some Prestige Consumer Healthcare metrics that are commonly tracked and projected by analysts on Wall Street.
Based on the collective assessment of analysts, 'Revenues- OTC Healthcare- International' should arrive at $35.94 million. The estimate indicates a year-over-year change of +8.4%.
Analysts' assessment points toward 'Revenues- OTC Healthcare- North American' reaching $224.16 million. The estimate suggests a change of -8.9% year over year.
The combined assessment of analysts suggests that 'Gross profit- OTC Healthcare- North American' will likely reach $123.36 million. The estimate compares to the year-ago value of $136.07 million.
It is projected by analysts that the 'Gross profit- OTC Healthcare- International' will reach $19.76 million. Compared to the present estimate, the company reported $18.61 million in the same quarter last year.
Over the past month, shares of Prestige Consumer Healthcare have returned -1% versus the Zacks S&P 500 composite's -6.7% change. Currently, PBH carries a Zacks Rank #4 (Sell), suggesting that it may underperform the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Seeking Clues to Prestige Consumer Healthcare (PBH) Q1 Earnings? A Peek Into Wall Street Projections for Key Metrics
Wall Street analysts forecast that Prestige Consumer Healthcare (PBH - Free Report) will report quarterly earnings of $0.87 per share in its upcoming release, pointing to a year-over-year decline of 17.9%. It is anticipated that revenues will amount to $260.07 million, exhibiting a decline of 6.9% compared to the year-ago quarter.
Over the last 30 days, there has been no revision in the consensus EPS estimate for the quarter. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Before a company reveals its earnings, it is vital to take into account any changes in earnings projections. These revisions play a pivotal role in predicting the possible reactions of investors toward the stock. Multiple empirical studies have consistently shown a strong association between trends in earnings estimates and the short-term price movements of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
With that in mind, let's delve into the average projections of some Prestige Consumer Healthcare metrics that are commonly tracked and projected by analysts on Wall Street.
Based on the collective assessment of analysts, 'Revenues- OTC Healthcare- International' should arrive at $35.94 million. The estimate indicates a year-over-year change of +8.4%.
Analysts' assessment points toward 'Revenues- OTC Healthcare- North American' reaching $224.16 million. The estimate suggests a change of -8.9% year over year.
The combined assessment of analysts suggests that 'Gross profit- OTC Healthcare- North American' will likely reach $123.36 million. The estimate compares to the year-ago value of $136.07 million.
It is projected by analysts that the 'Gross profit- OTC Healthcare- International' will reach $19.76 million. Compared to the present estimate, the company reported $18.61 million in the same quarter last year.
View all Key Company Metrics for Prestige Consumer Healthcare here>>>
Over the past month, shares of Prestige Consumer Healthcare have returned -1% versus the Zacks S&P 500 composite's -6.7% change. Currently, PBH carries a Zacks Rank #4 (Sell), suggesting that it may underperform the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>